Full text is available at the source.
Abstract
The UMBRAA strategy aims to mitigate the masking problem in psychedelic trials.
- UMBRAA stands for unidentifiable multidrug blinding with reduced, authorized awareness.
- This approach is designed to enhance the integrity of trial results by addressing issues of participant awareness.
- The strategy could potentially reduce biases associated with expectation and placebo effects in psychedelic research.
- Implementing UMBRAA may support more reliable comparisons between treatment and control groups.
Simplified